N,N dimethylacetamide a drug excipient that acts as bromodomain ligand for osteoporosis treatment

TitleN,N dimethylacetamide a drug excipient that acts as bromodomain ligand for osteoporosis treatment
Publication TypeJournal Article
Year of Publication2017
AuthorsGhayor C., Gjoksi B., Dong J., Siegenthaler B., Caflisch A., Weber F.E
JournalScientific Reports
Volume7
Pagination42108
Date Published2017 Feb 08
Type of ArticleResearch Article
ISSN2045-2322
Keywordsbromodomains, drug delivery, Drug Evaluation, epigenetics, inflammation, osteoporosis, Preclinical
Abstract

N,N-Dimethylacetamide (DMA) is a water-miscible solvent, FDA approved as excipient and therefore widely used as drug-delivery vehicle. As such, DMA should be devoid of any bioactivity. Here we report that DMA is epigenetically active since it binds bromodomains and inhibits osteoclastogenesis and inflammation. Moreover, DMA enhances bone regeneration in vivo. Therefore, our in vivo and in vitro data reveal DMA's potential as an anti-osteoporotic agent via the inhibition of osteoclast mediated bone resorption and enhanced bone regeneration. Our results highlight the potential therapeutic benefits of DMA and the need for reconsideration of previous reports where DMA was used as an 'inactive' drug-delivery vehicle.

DOI10.1038/srep42108
pubindex

0220

Alternate JournalSci. Rep.
PubMed ID28176838
PubMed Central IDPMC5296751
Highlight Role: 
Collaborations